NYSE Arca · SER
Serina Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for SER: Nov 12, 2026
Serina Therapeutics, Inc. Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. The reported EPS for the same quarter last year was $-0.45.
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Quiver Quantitative- RTTNews · Sep 9, 11:58 AM EDTSerina Reports Positive Cohort 1 Data For Phase 1 Evaluating Parkinson's Therapy(RTTNews) – Serina Therapeutics Inc. (SER), a clinical-stage biotechnology company, on Wednesday reported the completion of a blinded review evaluating Cohort 1 data from the Phase 1b trial for SER-252 in Parkinson's disease. Parkinson's patients treated with levodopa often exh
- RTTNews · Jul 23, 6:50 AM EDTSerina Appoints Simon To Board; Concludes Dosing In Phase 1b For Parkinson's Therapy SER-252(RTTNews) – Serina Therapeutics, Inc. (SER), a biotechnology company, on Wednesday announced the appointment of Farrell Simon to the Board of Directors, effective immediately.
- RTTNews · Jul 2, 10:09 AM EDTWeekly Buzz: VRTX, APTX Gain FDA Nod; UNCY Disappoints; Ipsen Opens Wallet; VTGN Misses Goal(RTTNews) – The holiday-shortened week delivered no shortage of action for the biotech sector, with a mix of FDA, China, Canada, and EU approvals, acquisitions, and positive clinical readouts, alongside regulatory rejections, program discontinuations, and trial goal misses.
- RTTNews · Jul 1, 3:52 AM EDTGannet BioChem Partners With Serina To Support SER-252 Development For Parkinson's Disease(RTTNews) – Gannet BioChem announced on Tuesday, that it has entered into a development partnership with Serina Therapeutics, Inc. (SER), a clinical-stage biotechnology company, to support the development of Serina's investigational therapy, SER-252, for the treatment of advanced
- RTTNews · Apr 6, 2:27 AM EDTNYSE Accepts Serina Therapeutics Continued Listing Compliance Plan(RTTNews) – Serina Therapeutics, Inc. (SER), a clinical-stage biotechnology company, reported that the NYSE American LLC has accepted the company's business plan to regain compliance with the continued listing standards of NYSE. Serina will now have until July 9, 2027, to regain
- RTTNews · Mar 18, 9:46 PM EDTSerina Therapeutics Secures $30M Financing To Advance Parkinson's Trial; Shares Jump 28% Overnight(RTTNews) – Serina Therapeutics, Inc. (SER) has entered into definitive agreements for a private placement of common stock and pre-funded warrants, raising up to $30 million to support its registrational trial of SER-252 in advanced Parkinson's disease.
- RTTNews · Feb 25, 3:05 AM ESTSerina Doses First Patient In Phase 1b Trial Of SER-252 For Advanced Parkinson's Disease(RTTNews) – Serina Therapeutics, Inc.(SER), a clinical-stage biotechnology company, announced that it has dosed the first patient in its Phase 1b registrational clinical trial evaluating SER-252 in patients with advanced Parkinson's disease.
- RTTNews · Feb 19, 7:36 AM ESTSerina Begins Phase 1b Registrational Trial Of SER-252 In Advanced Parkinson's(RTTNews) – Serina Therapeutics, Inc. (SER) announced that the first patient has been successfully enrolled in its global Phase 1b registrational trial of SER-252, an investigational therapy for advanced Parkinson's disease.
- RTTNews · Jan 29, 1:42 AM ESTSerina Jumps On FDA's IND Clearance For SER-252 In Advanced Parkinson's Disease After Clinical Hold(RTTNews) – Serina Therapeutics, Inc. (SER), a clinical-stage biotechnology company, shares climbed above 30% in the overnight trade after announcing that the U.S. Food and Drug Administration FDA has cleared its Investigational New Drug (IND) application for SER-252, its therapy
- RTTNews · Jan 16, 2:43 AM ESTSerina Therapeutics Receives NYSE Deficiency Notice; Stock Edges Down(RTTNews) – Serina Therapeutics, Inc. (SER), a clinical-stage biotechnology company, received a deficiency notice from the New York Stock Exchange (NYSE) for failing to meet the continued listing criteria, as it reported less than the minimum stockholders' equity of $2 million an
- RTTNews · Nov 3, 6:28 AM ESTWhy Is Serina Therapeutics Stock Falling In Pre-market?(RTTNews) – Serina Therapeutics (SER) announced that the FDA has placed a clinical hold on the Investigational New Drug application for SER-252, Serina's lead development program for advanced Parkinsons disease. The FDA has requested additional information related to a commonly u
- Quiver Quantitative · Jul 14, 8:21 AM EDTNew Analyst Forecast: $SER Given $15.0 Price TargetWe just received data on a new analyst forecast for $SER. Raghuram Selvaraju from HC Wainwright & Co. set a price target of 15.0 for SER.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Serina Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.